The online version of this article (https://doi.org/10.1007/s12325-018-0742-9) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.6507722.
Tumor necrosis factor (TNF) inhibitors are widely used biologics for the treatment of several chronic inflammatory diseases. The launch of anti-TNF biosimilars has introduced the possibility of non-medical switching between originator biologics and their biosimilars. However, the potential clinical and patient-reported consequences of non-medical switching remain largely unknown, as much of the evidence comes from poorly or uncontrolled real-world evidence (RWE) studies that often have an element of bias and nonstandardized outcome measures. To appropriately evaluate the safety, efficacy, and immunogenicity of non-medical switching from an originator to its biosimilar, we propose that seven key study design elements should be considered when assessing the existing evidence: studies should be (1) randomized and double-blind, (2) adequately controlled, and (3) adequately powered; include (4) multiple switching, (5) an assessment of immunogenicity, and (6) adequate follow-up duration; and (7) report individual patient-level outcomes. This systematic review assessed the robustness and consistency of the current non-medical switching evidence, with a focus on TNF inhibitors. A comprehensive literature search (January 2012–February 2018) identified 98 publications corresponding to 91 studies (17 randomized controlled trials and 74 RWE studies) describing non-medical switching from a TNF inhibitor originator to its biosimilar. When assessing the totality of this evidence, none of the non-medical switching studies conducted to date were found to use all seven of the key design elements, and the absence of these elements dilutes the robustness of the data. Furthermore, discontinuation rates varied widely among studies (0–87%), suggesting heterogeneity and inconclusiveness of the current efficacy, safety, and immunogenicity evidence, particularly at an individual patient level. Therefore, patients should not be indiscriminately switched from an originator TNF inhibitor to its biosimilar for non-medical reasons. Switching decisions should remain between the treating physicians and their patients and be made on a case-by-case basis, relying upon robust scientific evidence.
Plain Language Summary: Plain language summary available for this article.
Supplementary material 1 (PDF 218 kb)12325_2018_742_MOESM1_ESM.pdf
Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21:s331–40. PubMed
Reger A, Dube N. Non-medical switching of medications. Hartford, CT: Connecticut General Assembly, Office of Legislative Research; January 12, 2017. 2017-R-0008.
European Medicines Agency. Guideline on similar biological medicinal products (Revision). CHMP/437/04 Rev 1. London, UK: 2014.
US Department of Health and Human Services, US Food and Drug Administration. Guidance for industry scientific considerations in demonstrating biosimilarity to a reference product. Rockville, MD: US Dept of Health and Human Services; 2015.
World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 28 March 2018.
US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product Bethesda, MD: US Department of Health and Human Services. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. Accessed 10 April 2018.
List of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date. Center for Drug Evaluation and Research. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM560162.pdf. Accessed 10 April 2018.
National Conference of State Legislatures. State laws and legislation related to biologic medications and substitution of biosimilars. July 2015. http://www.ncsl.org/documents/summit/summit2015/onlineresources/BiologicsreportLS15newmedicines.pdf. Accessed 10 April 2018.
De Cock D, Kearsley-Fleet L, Watson K, Hyrich KL. Switching from RA originator to biosimilar in routine clinical care: early data from the British Society for Rheumatology biologics register for rheumatoid arthritis. Arthritis Rheumatol. 2017;69:3489–91.
European Medicines Agency policy on publication of clinical data for medicinal products for human use. EMA/240810/2013. October 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/WC500174796.pdf. Accessed 10 April 2018.
European Medicines Agency. European Public Assessment Reports (Biosimilars). http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed 10 April 2018.
Blauvelt A, Lacour JP, Fowler J, et al. Long-term efficacy, safety and immunogenicity results from a randomized, double-blind, phase III confirmatory efficacy and safety study comparing GP2017, a proposed biosimilar, with reference adalimumab [abstract]. Arthritis Rheumatol. 2017;69:abstr2440.
Cohen SB, Alonso-Ruiz A, Klimiuk PA, et al. Biosimilar candidate BI 695501 and adalimumab reference product have similar efficacy and safety in patients with moderately-to-severely active rheumatoid arthritis (RA): 1-year results from a phase III study. Arthritis Rheumatol. 2017;69:3495–7.
Cohen S, Pablos JL, Zhang N, et al. ABP 501 long-term safety/efficacy: interim results from an open-label extension study. Arthritis Rheumatol. 2016;68:808–9.
Genovese MC, Glover J, Matsunaga N, Chisholm D, Alten R. Efficacy, safety and immunogenicity in randomized, double-blind (DB) and open-label extension (OLE) studies comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product (Humira ®; RP) in patients (pts) with active rheumatoid arthritis (RA). Arthritis Rheumatol. 2017;69:abstr2799.
Hodge J, Tang H, O’Connor P, Finck B. Switching from adalimumab to CHS-1420: a randomized, double-blind global clinical trial in patients with psoriasis and psoriatic arthritis. Arthritis Rheumatol. 2017;69:abstr2879.
Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;177:1562–74. PubMedCrossRef
Weinblatt M, Baranauskaite A, Ghil J, Cheong SY, Hong E. Minimal and comparable radiographic progression by disease activity states in patients with rheumatoid arthritis who continued SB5 or reference adalimumab and who switched to SB5. Arthritis Rheumatol. 2017;69:abst2446. CrossRef
Weinblatt M, Baranauskaite A, Ghil J, Cheong SY, Hong E. Sustained efficacy and comparable safety and immunogenicity after transition to SB5 (an adalimumab biosimilar) vs. continuation of SB5 or reference adalimumab (Humira ®) in patients with rheumatoid arthritis: results of phase III study. Arthritis Rheumatology. 2016;68:790–2.
Griffiths CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928–38. PubMedCrossRef
Gerdes S, Thaci D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018;32:420–7. PubMedCrossRef
Goll G, Jørgensen KK, Sexton J, et al. Long-term safety and efficacy of biosimilar inliximab (CTP13) after switching from originator infliximab: results from the 26-week open label extension of a randomized Norwegian trial. Arthritis Rheumatol. 2017;69:abstr2800.
Kim Y, Ye BD, Pesegova M, et al. Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year maintenance and switching results. United Eur Gastroenterol J. 2017;5:1139–40.
Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018;77:234–40. PubMedCrossRef
Taylor P, Wyand M, Knight A, Costantino C, Lassen C. Efficacy of the biosimilar BOW015, compared to originator infliximab, initiated at moderate and severe disease activity thresholds in rheumatoid arthritis. Ann Rheum Dis. 2016;75:488–9.
Volkers A, Jansen J. SIMILAR trial—efficacy of infliximab-biosimilar compared to infliximab-biological in patients with inflammatory bowel disease in remission—a randomized, controlled, double blind, phase 4 noninferiority trial. United Eur Gastroenterol J. 2017;5:A307.
Alten R, Jones HE, Singh E, et al. Preliminary real world data on switching between etanercept and its recently marketed biosimilar counterpart. Value Health. 2017;20:A230. CrossRef
Alten R, Neregard P, Jones H, et al. Preliminary real world data on switching patterns between etanercept, its recently marketed biosimilar counterpart and its competitor adalimumab, using Swedish prescription registry. Arthritis Rheumatol. 2017;69:488.
Dyball S, Hoskins V, Christy-Kilner S, Haque S. Effectiveness and tolerability of Benepali in rheumatoid arthritis patients switched from Enbrel. Arthritis Rheumatol. 2017;69:3505–6.
Glintborg B, Omerovic E, Danebod K, et al. One-year clinical outcomes in 1623 patients with inflammatory arthritis who switched from originator to biosimilar etanercept—an observational study from the Danish Danbio Registry [abstract]. Arthritis Rheumatol. 2017;69:abstr1550.
Hendricks O, Hørslev-Petersen K. When etanercept switch fails—clinical considerations. Arthritis Rheumatol. 2017;69:3570–1.
Rabbitts R, Jewell T, Marrow KL, Herbison C, Laversuch C. Switching to biosimilars: an early clinical review. Rheumatology. 2017;56:132. CrossRef
Sigurdardottir VR, Husmark T, Svärd A. Switching from reference product to the biosimilar SB4 in a real life setting: 12 month follow up of 146 patients. Ann Rheum Dis. 2017;76:835.
Szlumper C, Laftah Z, Smith C, et al. Switching to biosimilar etanercept in clinical practice: a prospective cohort study. Br J Dermatol. 2017;177:62. CrossRef
Szlumper C, Topping K, Blackler L, et al. Switching to biosimilar etanercept in clinical practice. Rheumatology. 2017;56:ii139. CrossRef
Tweehuysen L, Huiskes VJB, Van Den Bemt BJF, et al. Open label transitioning from originator etanercept to biosimilar SB4 compared to continuing treatment with originator etanercept in a historical cohort in rheumatic diseases in daily practice. Arthritis Rheumatol. 2017;69:abstr2438. CrossRef
Akrout W, Bosycot A, Levet-Labry R, Gazaix-Fontaine E, Paul M, Claudepierre P. Transition from ongoing infliximab reference product to its biosimilar: can we talk about a failure? Rheum Dis. 2017;76:1301–2.
Ala K, Avery P, Wilson R, et al. Early experience with biosimilar infliximab at a district general hospital for an entire Crohn’s disease patient cohort switch from Remicade to Inflectra. Gut. 2016;65:A81. CrossRef
Babai S, Akrout W, Le-Louet H. Reintroduction of reference infliximab product in patients showing inefficacy to its biosimilar. Drug Saf. 2017;40:1027–8.
Batticciotto A, Antivalle M, Li Gobbi F, et al. Safety and efficacy of switching from originator to CT-P13 infliximab biosimilar in patients affected by spondyloarthritis. A 6-month observational study. Arthritis Rheumatol. 2016;68:957–8.
Bennett KJ, Heap GA, Hawkins S, Ahmad T. Prospective evaluation of the safety and efficacy of switching stable patients with inflammatory bowel disease from Remicade™ to biosimilar infliximab (IFX). Gut. 2016;65:A146. CrossRef
Boone N, Lui L, Romberg M, et al. Transition study of biosimilar infliximab in patients with inflammatory bowel disease. Clin Ther. 2017;39:e9. CrossRef
Choe YH, Yang HR, Moon JS, et al. Effectiveness and safety of CT-P13 under routine care in paediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:S396. CrossRef
Choe YH, Lee SH, Park DI, et al. Effectiveness and safety in Crohn’s disease patients who were treated with CT-P13. Gastroenterology. 2017;152:S406. CrossRef
Chung L, Arnold B, Johnson R, Lockett MJ. Making the change: switching to infliximab biosimilars for IBD at North Bristol NHS trust. Gut. 2016;65:A22–3. CrossRef
Díaz Hernández L, Rodríguez González GE, Vela González M, et al. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months [abstract P449]. J Crohn’s Colitis. 2016;10:S327.
Ellis LA, Simsek I, Xie L, et al. Analysis of real-world treatment patterns in a matched sample of rheumatology patients with continuous infliximab therapy or switched to biosimilar infliximab. Arthritis Rheumatol. 2017;69:abstr455. CrossRef
Fiorino G, Radice S, Gilardi D, et al. Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study. J Crohns Colitis. 2017;11:S320. CrossRef
Forejtová S, Zavada J, Szczukova L, Jarosova K, Philipp T, Pavelka K. A non-medical switch from originator infliximab to biosimilar CT-P13 in 36 patients with ankylosing spondylitis: 6-months clinical outcomes from the Czech biologic registry Attra. Arthritis Rheumatol. 2017;69:2198–201.
Geccherle A, Tessari R, Variola A, Massella A, Capoferro E, Zuppini T. A single-center experience with biosimilar infliximab: clinical, pharmacological and economic aspects. Tech Coloproctol. 2017;21:834.
Gentileschi S, Barreca C, Bellisai F, et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases. Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683. Expert Opin Biol Ther. 2016;16:1311–2. PubMedCrossRef
Giunta A, Manfreda V, Del-Duca E, Vollono L, Di-Raimondo C, Bianchi L. A comparative study evaluating efficacy and safety of the biosimilar of infliximab in psoriatic patients: naive to biosimilar versus patients previously treated with the originator. Presented at: European Academy of Dermatology and Venereology; September 13–17, 2017; Geneva, Switzerland.
Gompertz M, Alfaro L, Ricart E, et al. Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment. J Crohn’s Colitis. 2017;11:S427–8. CrossRef
Hamanaka S, Nakagawa T, Koseki H, et al. Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single cohort observational study. J Crohn’s Colitis. 2016;10:S260.
Hlavaty T, Krajcovicova A, Sturdik I, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases—a one-year, single-centre retrospective study. Gastroenterol Hepatol. 2016;70:27–36. CrossRef
Holroyd C, Parker L, Bennett S, et al. Switching to biosimilar infliximab: real-world data from the Southampton biologic therapies review service. Rheumatology. 2016;55:i60–1.
Huoponen S, Eberl A, Räsänen P, et al. Switching maintenance-infliximab to biosimilar-infliximab does not lead to significant changes in health-related quality of life and clinical outcomes in inflammatory bowel disease patients. Value Health. 2017;20:A545. CrossRef
Malaiya R, McKee Z, Kiely P. Infliximab biosimilars—switching Remicade to Remsima in routine care: patient acceptability and early outcome data. Rheumatology. 2016;55:abstr158.
Malpas A, Steel L, Mills K, Pathak H, Gaffney K. Switching from Remicade to biosimilar infliximab: an evaluation of efficacy, safety and patient satisfaction. Rheumatology. 2017;56:ii69. CrossRef
Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–83. PubMedCrossRef
Nugent S, Nugent M, Mullane D, Kelly C. EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experience. J Crohn’s Colitis. 2017;11:S295. CrossRef
Phillips K, Juday T, Zhang Q, Keshishian A. Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or CT-P13 in the Turkish population. Ann Rheum Dis. 2017;76:SAT0172.
Plevris N, Deekae A, Jones GR, et al. A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: The Edinburgh experience. Gastroenterology. 2017;152:S385. CrossRef
Presberg Y, Foltz V, L’Amour C, et al. THU0646 Interchangeability from infliximab originator to infliximab biosimilar: efficacy and safety in a prospective observational study on 89 patients. Ann Rheum Dis. 2017;76:450. CrossRef
Rahmany S, Cotton S, Garnish S, et al. In patients with IBD switching from originator infliximab (remicade) to biosimilar infliximab (CT-P13) is safe and effective. Gut. 2016;65:A89.
Ratnakumaran R, To N, Gracie D, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. United Eur Gastroenterol J. 2017;5:A524.
Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11:690–6. PubMed
Rubio E, Ruiz A, López J, et al. Prospective study of 78 patients treated with infliximab biosimilar Remsima ®. Ann Rheum Dis. 2016;75:1006. CrossRef
Sheppard M, Hadavi S, Hayes F, Kent J, Dasgupta B. Preliminary data on the introduction of the infliximab biosimilar (CT-P13) to a real world cohort of rheumatology patients. Ann Rheum Dis. 2016;75:1011. CrossRef
Sieczkowska-Golub J, Jarzebicka D, Dadalski M, Meglicka M, Oracz G, Kierkus J. Maintenance biosimilar infliximab therapy in Crohn’s disease pediatric patients after switching from original molecule. J Pediatr Gastroenterol Nutr. 2017;65:S23. CrossRef
Sieczkowska J, Jarzȩbicka D, Oracz G, Meglicka M, Dadalski M, Kierkus J. Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62:354. CrossRef
Sladek M, Vultaggio A, Ghione S, et al. Efficacy, safety and immunogenicity of CT-P13 following transition from reference infliximab (Remicade) in children with established inflammatory bowel disease: a multi-centre prospective, observational study. J Pediatr Gastroenterol Nutr. 2017;64:52. CrossRef
Strik AS, Van De Vrie W, Megen Y, Minekus J, Rispens T, D’Haens GR. Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent Crohn’s disease: a prospective study. Gastroenterology. 2017;152:S66. CrossRef
Toscano Guzmán MD, Sierra Torres MI, Flores Moreno S, Avila Carpio AD, Romero Gomez M, Bautista Paloma FJ. Effectiveness and safety of biosimilar infliximab in ulcerative colitis. Eur J Hosp Pharm. 2016;23:A152. CrossRef
van den Hoogen FHJ, Tweehuysen L. Introduction of biosimilars in a rheumatological practice: first findings. Nederlands Tijdschrift voor Dermatologie en Venereologie. 2016;26:135–6.
Yazici Y, Xie L, Ogbomo A, et al. A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab [abstract SAT0175]. Arthritis Rheumatol. 2016;68:2903–6.
Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55:523–34.
US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 3 April 2018.
The VOLTAIRE-X trial looks at the effect of switching between Humira ® and BI 695501 in patients with plaque psoriasis. https://clinicaltrials.gov/ct2/show/NCT03210259. Accessed 30 Jan 2018.
Boehringer Ingelheim Press Release. Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA ® [press release]. https://www.boehringer-ingelheim.com/press-release/interchangeability-study-bi-695501-vs-humira. Accessed 3 April 2018.
Considerations for physicians on switching decisions regarding biosimilars. European Biopharmaceutical Enterprises; European Federation of Pharmaceutical Industries and Associations; International Federation of Pharmaceutical Manufacturers and Associations. https://www.ebe-biopharma.eu/wp-content/uploads/2017/04/considerations-for-switching-decisions_biosimilars-and-rbps-final-branded-1.pdf. Accessed 3 April 2018.
European Medicines Agency, European Commission. Biosimilars in the EU. Information guide for healthcare professionals. London, UK: European Medicines Agency, European Commission; 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf. Accessed 3 April 2018.
Comparison of CHS-1420 versus Humira in subjects with chronic plaque psoriasis (PsOsim). https://clinicaltrials.gov/ct2/show/NCT02489227. Accessed 3 April 2018.
Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–12. PubMedPubMedCentralCrossRef
Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–20. PubMedPubMedCentralCrossRef
- Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II